Tumor News and Research

RSS

TheScientist honors Seahorse Bioscience's XF96 Extracellular Flux Analyzer as a 2009 Top Ten Innovation

Seahorse Bioscience, Inc., leader in the design and development of instruments for measuring cellular bioenergetics, announced that TheScientist magazine cited their XF96 Extracellular Flux Analyzer as a 2009 Top Ten Innovation.

30 Dec 2009

Results from Bionovo's study on BN107 published

Bionovo, Inc. announced today the publication of results from its study on the anti-tumor mechanism of BN107. The results of the study, published in the International Journal of Cancer, describe the potential molecular mechanisms mediating the selective pro-apoptotic (cell death) effect induced by BN107 on estrogen receptor negative (ER-) breast cancer cells.

29 Dec 2009

Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer

The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis’ therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.

29 Dec 2009

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin to GE Healthcare. Under the license GE will further evaluate and develop the technology and will have an option to commercialize the technology. The technology, using imaging probes with a radiopharmaceutical compound, was invented by Ming Zhao, Ph.D., assistant professor of biophysics.

29 Dec 2009

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Compugen Ltd. announced today the discovery and experimental validation of CGEN-671, a new drug target for multiple epithelial tumors.

28 Dec 2009

Self-seeding process of cancer cells can enhance tumor growth, says study

Cancer progression is commonly thought of as a process involving the growth of a primary tumor followed by metastasis, in which cancer cells leave the primary tumor and spread to distant organs.

27 Dec 2009

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Inhibition of transcription factor E2F1 reduced epidermal growth factor receptor (EGFR) expression and reduced the invasive potential but not proliferation of metastatic melanoma cells, according to a brief communication published online December 23 in the Journal of the National Cancer Institute.

24 Dec 2009

Study suggests routine evaluation does not predict prostate cancer

On the heels of the American Cancer Society's recent controversial response to breast and prostate cancer screenings guidelines, a new study from the Mayo Clinic has emerged analyzing the correlation between prostate-specific antigen (PSA) levels and prostate size. The study discovered that routine annual evaluation of prostate growth does not predict the development of prostate cancer.

24 Dec 2009

New compound may halt drug-resistant lung cancer

The ability to make, test, and map the atomic structure of new anti-cancer agents has enabled a team of Dana-Farber Cancer Institute scientists to discover a compound capable of halting a common type of drug-resistant lung cancer.

24 Dec 2009

Discovery enables scientists to devise novel strategies to diagnose and treat brain cancer

A team of Columbia scientists have discovered two genes that, when simultaneously activated, are responsible for the most aggressive forms of human brain cancer.

23 Dec 2009

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it is initiating a Phase 2 clinical study of STA-9090 in patients with advanced gastrointestinal stromal tumors (GIST). This is the sixth clinical study of STA-9090, a potent, synthetic, small molecule Hsp90 inhibitor with a novel chemical structure.

23 Dec 2009

Rigel Pharmaceuticals announces milestone payment from Daiichi Sankyo

Rigel Pharmaceuticals, Inc. today announced that it has received a milestone payment from Daiichi Sankyo Co., Ltd. as part of their collaboration to research and develop cancer treatments aimed at selectively inhibiting ligases, which are intrinsic to cancer cell growth and proliferation. The compound, as yet unnamed, targets cell division.

23 Dec 2009

Comprehensive review of cell migration

Cell migration is a highly complex process which involves several compartments of the cell, including surface receptors, signalling elements and the cytoskeleton.

23 Dec 2009

Nationwide Children's Hospital chosen as a BCR for TCGA

Nationwide Children's Hospital recently was awarded an initial $5.5 million contract from the National Cancer Institute (NCI) to serve as a Biospecimen Core Resource (BCR) for The Cancer Genome Atlas (TCGA), a program co-managed by the NCI and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH).

23 Dec 2009

Novel discovery offers hope for patients with common brain tumor

Biomedical researchers at the University of Central Florida have found a protein that could hold the key to treating one of the most common and aggressive brain tumors in adults.

23 Dec 2009

Enzyme dCK plays a profound role in normal lymphocyte development

Mice without the deoxycytidine kinase (dCK) enzyme have defects in their adaptive immune system, producing very low levels of both T and B lymphocytes, the major players involved in immune response, according to a study by researchers with UCLA's Jonsson Comprehensive Cancer Center.

23 Dec 2009

UPMC reports 10,000th patient treated using Elekta's Leksell Gamma Knife system

On the morning of December 17, 2009, UPMC physicians used Gamma Knife® surgery to treat the center's 10,000th patient, an 81-year-old male with a tumor deep in his brainstem, a site where traditional surgery would have been impossible. Gamma Knife surgery is performed using Elekta's Leksell Gamma Knife system, which directs up to 201 pencil-thin beams of therapeutic radiation precisely on brain tumors and other targets in the head.

From Elekta 23 Dec 2009

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

No two tumors are alike, but analyzing the genetics of cancers from different parts of the body may reveal surprising details useful for treatment and prevention.

22 Dec 2009

Safe Cell Phone's SAR Shield absorbs potentially harmful cell phone radiation

The World Health Organization (WHO) announced on October 26, 2009 that its 10 year study has shown a proven link between long term cell phone usage and increased risks in brain cancer and tumors. The ten year study headed by Dr. Elisabeth Cardis shows a 18% increase in brain tumor development with long term cell phone usage.

22 Dec 2009

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Four cancer patients became the first in Latin America to receive treatment using a fast form of image-guided radiotherapy that potentially enables doctors to improve outcomes while extending modern care to more patients. Doctors at Hope International Centro de Radioterapia of Guatemala are now treating four patients using RapidArc® radiotherapy technology from Varian Medical Systems, one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme--an aggressive type of brain tumor.

22 Dec 2009

Tumor News and Research

TheScientist honors Seahorse Bioscience's XF96 Extracellular Flux Analyzer as a 2009 Top Ten Innovation

Results from Bionovo's study on BN107 published

Advaxis reports 3-year survival data from its ADXS11-001 Phase I trial for cervical cancer

The Medical College of Wisconsin licenses novel molecular imaging technology to GE Healthcare

CGEN-671, a new drug target for multiple epithelial tumors discovered by Compugen

Self-seeding process of cancer cells can enhance tumor growth, says study

E2F1 transcription factor inhibition reduces EGFR expression and invasive potential of melanoma cells

Study suggests routine evaluation does not predict prostate cancer

New compound may halt drug-resistant lung cancer

Discovery enables scientists to devise novel strategies to diagnose and treat brain cancer

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Rigel Pharmaceuticals announces milestone payment from Daiichi Sankyo

Comprehensive review of cell migration

Nationwide Children's Hospital chosen as a BCR for TCGA

Novel discovery offers hope for patients with common brain tumor

Enzyme dCK plays a profound role in normal lymphocyte development

UPMC reports 10,000th patient treated using Elekta's Leksell Gamma Knife system

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

Safe Cell Phone's SAR Shield absorbs potentially harmful cell phone radiation

Four Latin American cancer patients receive treatment using RapidArc radiotherapy technology

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News